S169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES. (23rd June 2022)

• Record Type: Journal Article
• Authors: Kubasch, A. S.; Giagounidis, A.; Metzgeroth, G.; Jonasova, A.; Herbst, R.; Diaz, J. M. T.; De Renzis, B.; Götze, K. S.; Huetter-Kroenke, M.-L.; Gourin, M.-P.; Slama, B.; Dimicoli-Salazar, S.; Cony-Makhoul, P.; Laribi, K.; Park, S.; Jersemann, K.; Schipp, D.; Metzeler, K. H.; Tiebel, O.; Sockel, K.; Gloaguen, S.; Mies, A.; Chermat, F.; Thiede, C.; Sapena, R.; Schlenk, R. F.; Fenaux, P.; Platzbecker, U.; Ades, L.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 70
• Page End: 71
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000843568.62728.76
• Languages: English
• ISSNs: 2572-9241